AiLNP

AiRNA

AiTEM

AI驱动`药物递送`和`药物发现`

AI-driven `Drug Delivery` and `Drug Discovery`

专注“AI+药物递送”的创新型生物技术公司剂泰医药宣布完成1亿美元C轮融资，本轮融资由中金资本旗下基金领投，中国太平旗下太平香港保险科创基金跟投。加上此前已获得的红杉中国、国寿股权、人保股权、五源资本、峰瑞资本、源码资本、光速光合、砺思资本等顶尖投资机构投资，剂泰医药累计融资近3亿美元。

剂泰医药宣布完成1亿美元C轮融资

剂泰医药被授予中国卒中学会“脑科学与多组学研究”创新合作单位称号。

剂泰医药获中国卒中学会“脑科学与多组学研究”创新合作单位授牌

<a href="https://oss.metispharmaceuticals.cn/8b7548924bddec55e7690ef05e403bc3.zip" target="_blank">0.zip</a>The 16th CCKS was held in Qinhuangdao on August 26, 2022. CCKS technology evaluation aims to provide a platform and resources for researchers to test knowledge graph and semantic computing technologies, algorithms and systems, bolster the technological development in the field of knowledge graph in China, and promote the integration and coordination of academic achievements and industrial needs. The official announcement disclosed that there are 14 evaluation tasks in this year, encompassing 5 topics in fields of finance, education, military, chemical and etc.; 5,362 teams with nearly 23,000 people participated in the competition. Yang Wenming, Yin Le and Zou Jiali, members of the AI department of METiS Pharmaceuticals, stood out from many other teams and won the evaluation task competition of &quot; Construction and Application of Chemical Elemental Knowledge Graph &quot; with absolute superiority. <div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/3f90a203beea45df01711b79608907a9.jpg" width="682.484px" height="478px" style="width:682.484px;height:478px"/></div><div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/69a2e8b1bd3a2358a3c89630894e55cd.jpg" width="662px" height="440.988px" style="width:662px;height:440.988px"/></div>The main intention of compound property prediction is to find compounds with substandard physical and chemical properties in a short time, so as to reduce risk when candidates entering into clinical trials and improve the drug development success rate. The traditional method of compound property prediction and analysis is usually from experiments, which is costly and time-consuming. A lot of research work has proved that the machine learning technology, especially the depth study on compound property prediction, has huge utilization potential. The drug research and development work are implemented by using sequence (SMILES) or graphs (atomic for the node, chemical bonds for edge) to indicate compounds, and leveraging sequence modeling or graph neural network (GNN) to predict the properties of the compound, so as to improve the efficiency and reduce the research cycle. However, these approaches usually only take the structural information of compound molecules into consideration not the chemical knowledge. Therefore, the organizer constructed the chemical element knowledge graph based on the periodic table of chemical elements, and brought forward the evaluation tasks in regard to the key technologies and applications of the knowledge graph construction.METiS team exploited the following approaches to study the compound molecules: 1) Graph data pre-training technology, the atoms in the molecule are regarded as nodes, chemical bonds as edges, and the chemical molecule as a graph data; 2) Molecular descriptors; 3) Pharmacophore fingerprints. In the pre-training model, 2D information, 3D information and functional groups, etc. of chemical molecules are included comprehensively. Based on the above different approaches, feature vectors are generated to characterize molecules. Secondly, descending the high dimensional sparse vectors (functional group) into lower dimensional dense ones, then integrate these vectors that with various features to generate the ultimate vector characteristic. Lastly, import those vector characteristics for prediction from integrated model, which foretell a precise compound characteristic. Refer to the ensuing disclosed evaluation paper in CCKS2022 for specific methods.“Compound property prediction based on multiple different molecular features and ensemble learning”（website：www.sigkg.cn/ccks2022）<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/bd02f5344ccec74a51b2b505358b6b8d.png" width="877.491px" height="268px" style="width:877.491px;height:268px"/></div>Schematic Diagram for Molecular CharacterizationThe integration of Pharmacoprint (Gobbi) can improve the final evaluation metrics, but pharmacophore fingerprint is a high-dimensional sparse vector, mainly composed of 0 or 1. For such features with excessive dimensions, AutoEncoder is used to reduce dimension, and label information is also fully used in the process of dimension reduction. The model structure is shown in the following figure. The processed molecular characteristics are spliced and merged, and then import into the model for training.<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/d51023379ed300462f4b62ebe9ce7e82.png" width="597.993px" height="362px" style="width:597.993px;height:362px"/></div>The winning demonstrated that METiS has made great progress in the field of AI pharmaceutical in terms of the capability of algorithm and model building .<div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/5561f75be6f8f25b1273098cdebd8f2c.png" width="823px" height="204.479px" style="width:823px;height:204.479px"/></div>Now, the team&#x27;s technical solution has been successfully applied to the AiLNP &amp; AiTEM , two core technology platform of METiS. It is an efficient supportive tool for prediction of LNP and solid dispersion system, enabling &quot;AI + pharmaceutical&quot;, shortening the development cycle, improving the R&amp;D efficiency, to achieve more effective innovational delivery material design and more advantageous formulation system. In the future, METiS will endeavor to make great efforts in fundamental research and pharmaceutical R&amp;D in AI pharmaceutical by virtue of its leading scientific research and innovation ability, continue exploring the uncharted area of biology and pharmaceutical benefit from AI technology, to ultimately address the unmet clinical needs. About usMETiS is a biotechnology company that aims to drive optimal therapies across a broad spectrum of diseases by combining drug delivery and drug discovery with artificial intelligence, machine learning, and quantum simulation to address unmet clinical needs. The core team is led by NAE member and a number of MIT scientists, including drug development experts from well-known pharmaceutical companies such as Regeneron, Amgen and Novartis, as well as young talents in artificial intelligence and computing. The participants, Wenming Yang and Jiali Zou, also won the third place in the evaluation task of Medical Named Entity Recognition of CCKS2020.Based on the underlying technology, METiS has built the proprietary core technology platform of AiLNP, AiRNA and AiTEM to predict the physical and chemical and biological characteristics of small molecules and nucleic acid-based drugs in a specific microenvironment. METiS harnessed AI to drive the dry and wet experiment iteration to achieve more effective innovative design, especially in delivery material, nucleic acid sequence and optimization, for a more superior formulation and nucleic acid-based delivery system.AiLNP:AiLNP is an independent developed and self-owned platform, LNP library with a magnitude of tens of thousands of cationic lipids, and it is with independent IP rights of LNP delivery systems. The expression efficiency surpasses the industry standard for more than ten times. At the same time, LNP-based delivery targeting liver, lung, spleen, muscle and organs, tissues, etc., will enable the therapeutics such as, local regeneration, systematic, targeted protein secretion, antibody, enzyme replacement, tumor targeting, and enhance the immune therapy. The delivery and technology success has brought about a number of pipeline cooperation opportunities either from domestic or foreign large pharmaceutical companies.AiRNA: AiRNA uses quantum chemistry and machine learning algorithms, and combines the biological and physicochemical properties of nucleic acids to enhance large-scale design of the full-length mRNA sequence space. It is an mRNA synthesis and purification platform where mRNAs can be rapidly produced, tested in vivo and in vitro, optimized through AI models and experimental iterations, and eventually the mRNA sequences with high stability and high expression efficiency can be effectively designed.AiTEM: AiTEM establishes large-scale design space of formulations. It can generate tens of thousands of formulations per week and obtain the optimal ones within one month. By developing formulations such as solid dispersions, pharmaceutical gels, self-emulsifying granules, and nanoemulsions, or by solubilizing the insoluble compounds, the problems of insoluble and impermeable drugs can be solved.

团队的技术方案已成功运用到剂泰医药的核心技术平台AiLNP和AiTEM中，高效支撑脂质体LNP预测和固分体体系预测两大技术模块。

Now, the team's technical solution has been successfully applied to the AiLNP & AiTEM , two core technology platform of METiS. It is an efficient supportive tool for prediction of LNP and sol

剂泰医药斩获 CCKS 2022 化学知识图谱构建和应用评测冠军

A Recognition from CCKS2022, METiS Snagged First Prize for its Construction and Application of Chemical Elemental Knowledge Graph

<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/921f0d4aa304a252ab53f5bcb8396d7f.gif" width="393" height="168" style="width:393px;height:168px"/></div>With the theme of &quot;Unite Global Startups, Empower Beijing Innovations&quot;, HICOOL 2022 Global Entrepreneurs Summit was held in Beijing from August 26 to 28. HICOOL 2022 Global Entrepreneurship Competition announced the final list of winners, including 7 first prize winners, 21 second prize winners, 42 third prize winners and other 70 prizes. The project named as &quot;AI-driven Drug Delivery and Drug Discovery&quot; initiated by Dr. Lai Caida and Dr. Wang Wenshou, founders of METiS, won the first prize, the highest award among all the competition.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/ddf26ed85690a359b8ba76daa98ec543.png"/></div>About HICOOL 2022 Global Entrepreneurship CompetitionHICOOL is a one-stop ecological platform for entrepreneurship sponsored by Beijing Overseas Talents Association (BOTA). Competitions, summit, ecosystem and other modes provided supportive approaches to consolidate the work of talent mining, talent introduction, talent services and talent protection, which enables technology-driven entrepreneurship and value-driven innovation. It is a high-profile competition which attracts 91 countries and regions, 5,016 entrepreneurial projects and 6,672 entrepreneurial talents to participate; It covers seven professional industry areas, artificial intelligence/virtual reality/financial technology, medicine and healthcare, new generation of information technology, cutting-edge equipment, new energy/new materials/energy conservation and environmental protection, cultural creativity, agricultural science and technology/food technology. The competition usually invites top investors, well-known panels and top entrepreneurs to provide the whole process of entrepreneurship guidance and ability to accelerate projects. More excitingly, it provides thoughtful &quot;Beijing Services&quot;, such as talent residency, children&#x27;s education service, medical insurance and talent apartment, so as to continuously empower entrepreneurs.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/84636602b9f894212918764773ca308d.png"/></div><div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/10fec7d3f04dfa2109ac312508d44802.jpg" width="635" height="347" style="width:635px;height:347px"/></div>On the evening of June 26, Dr. Lai Caida, Co-founder and CEO of, METiS, attended the HICOOL 2022 Global Entrepreneurship Competition Award Ceremony and delivered an electric speech. He said, &quot;It is a great honor for the team to win the first prize. The gratifying R&amp;D progress of METiS not only benefit from the core technology platform and core team, but also the favorable pharmaceutical environment of Beijing, and the high-quality supportive resources provided by the industrial park and the talent subsidy policies of relevant government authorities. We believe that with the HICOOL Entrepreneurship Competition platform and the outstanding resource integration capability of the organizers, many high-quality entrepreneurial teams domestically or abroad will be in the limelight, and they will fully demonstrate their technological innovation with a burgeoning growth.&quot;On the afternoon of 28th, Dr. Lai was invited to attend the &quot;Global Entrepreneur Day&quot; of HICOOL 2022 Global Entrepreneurs Summit. He gave a ‘flash mob roadshow’ to present the content and highlights of the winning project.The name of the project is &quot;AI-driven Drug Delivery and Drug Discovery&quot;. METiS, as the world&#x27;s first innovational AI-driven drug delivery and drug discovery biotechnology company, on the one hand, is developing small molecule drugs by improving the drug biological availability, stability, forms and new carrier system to overcome the hurdles of small molecule drugs, aiming to design reformulated novel drugs with clinical individual differentiation. On the other hand, it challenges the long-hold mindset from molecular design to drug delivery, an inevitable process of new modality drugs. It deeply set about the new modality drugs process from encoding, DNA, RNA, then to protein, enabling the products to be stably delivered to the target organs to achieve precise targeting and treatment.Now, the company has applied for a number of patents with crucial application value, and deployed a number of small molecule and nucleic acid research and development pipelines, among which the pipeline with faster progress is expected to carry out pivotal clinical trials in 2023. It is worth mentioning that METiS has built the capability of nucleic acid drug development with the integration of mRNA sequence design and LNP delivery system design with its independent intellectual property rights. The expression efficiency of its LNP nucleic acid delivery system is more than ten times higher than the industry gold standard, and it also achieves targeted delivery to liver, lung, spleen, muscle and other organs or tissues. From that, it enables METiS to achieve local regeneration, systemic/targeted protein secretion, antibody, enzyme replacement, tumor targeting, immunoenhancement and other treatments, which has brought a number of pipeline collaboration opportunities from domestic and foreign large pharmaceutical companies.METiS has outshined from many high-quality projects in HICOOL 2022 Global Entrepreneurship Competition with the first prize bagged, which fully demonstrated the high innovation level of the company&#x27;s core technology platform and its wide application and development prospects. We believe that under the drive of HICOOL platform and high-quality resources, METiS will have a further development in terms of cooperate development, R&amp;D innovation, and talent benefits, etc. The enterprise will not fail the recognition from the honorary award. METiS will keep on solving the unmet clinical needs for the patients with more high-quality therapeutics, parlaying the platform benefits from the integration of artificial intelligence, machine learning, quantum simulation and other cutting-edge technologies.

HICOOL 是由北京海外高层次人才协会作为主办方的一站式创业生态平台，参赛报名范围覆盖全球91个国家和地区、5016个创业项目、6672位创业人才。

HICOOL is a one-stop ecological platform for entrepreneurship sponsored by Beijing Overseas Talents Association (BOTA).It is a high-profile competition which attracts 91 countries and regions

剂泰医药项目荣获HICOOL 2022全球创业大赛海外组一等奖

METiS Bagged Oversea Group First Prize in 2022 HICOOL Global Entrepreneurship Competition 

杭州剂泰医药科技有限责任公司

核心技术

业务|Business

管线|Pipeline

剂泰医药宣布完成1亿美元C轮融资

剂泰医药获中国卒中学会“脑科学与多组学研究”创新合作单位授牌

剂泰医药斩获 CCKS 2022 化学知识图谱构建和应用评测冠军

剂泰医药项目荣获HICOOL 2022全球创业大赛海外组一等奖